These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Avandia in perspective. Comarow A US News World Rep; 2007 Oct; 143(11):71. PubMed ID: 17957906 [No Abstract] [Full Text] [Related]
23. [Glitazones more than hypoglycemics in type 2 diabetes]. Sjöholm A Lakartidningen; 2007 Oct 24-30; 104(43):3201-3. PubMed ID: 18018938 [No Abstract] [Full Text] [Related]
24. Fluid retention with thiazolidinediones: does the mechanism influence the outcome? Lindenfeld J; Masoudi FA J Am Coll Cardiol; 2007 Apr; 49(16):1705-7. PubMed ID: 17448372 [No Abstract] [Full Text] [Related]
25. [Don't judge all glitazones alike!]. Sjöholm A Lakartidningen; 2007 Oct 24-30; 104(43):3205. PubMed ID: 18018940 [No Abstract] [Full Text] [Related]
26. Cardiovascular effects of the thiazolidinediones. Qayyum R; Schulman P Diabetes Metab Res Rev; 2006; 22(2):88-97. PubMed ID: 16184618 [TBL] [Abstract][Full Text] [Related]
28. A lesson in moderation: applying pharmacodynamics to clarify the relationship between thiazolidinediones and adverse vascular outcomes in type 2 diabetes. Lehmann DF; Lohray BB J Clin Pharmacol; 2008 Aug; 48(8):999-1002. PubMed ID: 18650500 [No Abstract] [Full Text] [Related]
29. [The benefit of pioglitazone in patients with diabetes mellitus type 2 and cardiovascular complications]. Olsovský J Vnitr Lek; 2005 Dec; 51(12):1412. PubMed ID: 16430111 [No Abstract] [Full Text] [Related]
30. Actos and Avandia in type 2 diabetes. Where do they fit? Clark W Diabetes Self Manag; 2007; 24(4):8, 11-3. PubMed ID: 17663078 [No Abstract] [Full Text] [Related]
31. Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College Of Cardiology Foundation. Kaul S; Bolger AF; Herrington D; Giugliano RP; Eckel RH; ; J Am Coll Cardiol; 2010 Apr; 55(17):1885-94. PubMed ID: 20413044 [No Abstract] [Full Text] [Related]
32. [Treatment of patients with type 2 diabetes mellitus with pioglitazone. A survey of a Cochrane review]. Madsbad S Ugeskr Laeger; 2007 Nov; 169(47):4054-7. PubMed ID: 18078659 [No Abstract] [Full Text] [Related]
34. Type 2 diabetes, thiazolidinediones, and cardiovascular risk. Taylor C; Hobbs FD Br J Gen Pract; 2009 Jul; 59(564):520-4. PubMed ID: 19567003 [TBL] [Abstract][Full Text] [Related]
35. Diabetes and heart failure: the role of thiazolidinediones in managing these partners in crime. Leier CV; Haas GJ J Am Coll Cardiol; 2007 Jul; 50(1):37-9. PubMed ID: 17601543 [No Abstract] [Full Text] [Related]
36. Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence? Patel C; Wyne KL; McGuire DK Diab Vasc Dis Res; 2005 May; 2(2):61-6. PubMed ID: 16305060 [TBL] [Abstract][Full Text] [Related]
38. Should we now ADOPT glitazones earlier in treatment of type 2 diabetes? Howat I; Cleland SJ Int J Clin Pract; 2007 Jul; 61(7):1071-3. PubMed ID: 17577291 [No Abstract] [Full Text] [Related]
39. Thiazolidinediones and heart failure: a teleo-analysis. Singh S; Loke YK; Furberg CD Diabetes Care; 2007 Aug; 30(8):2148-53. PubMed ID: 17536074 [TBL] [Abstract][Full Text] [Related]
40. The rosiglitazone controversy: the Indian perspective. Mohan V; Joshi SR J Assoc Physicians India; 2007 Jul; 55():477-80. PubMed ID: 17907495 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]